Report Detail
Global Dyslipidemia Drugs Market Research Report 2019
- RnM3108034 |
- 12 March, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual.
The increasing risk of cardiovascular disease (CVDs) is the primary driver for the market’s growth. Elevated cholesterol levels account for nearly one-third of the total ischemic heart diseases and persist as a substantial cause of ischemic heart diseases and strokes in emerging countries such as India and China. Thus, the cardiovascular risk management guidelines set by authorities such as the American College of Cardiology and American Heart Association acknowledge the decreasing the blood cholesterol as a prime factor in cutting down on the cardiovascular risks. This, in turn, drives the cholesterol maintaining drugs to avoid CVDs risk and boosting the sales of the drugs market.
With the presence of numerous small and larger vendors, the global dyslipidemia drugs market is largely competitive. Competition is observed from the regional players globally, and there are numerous new manufacturers entering the market. Moreover, companies like Amgen, HanAll BioPharma, Kowa Pharmaceuticals, CJ HealthCare, Catabasis Pharmaceuticals, JW Pharmaceuticals, and Esperion Pharmaceuticals are expected to enter the market over the next four years.
The global Dyslipidemia Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dyslipidemia Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dyslipidemia Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
AstraZeneca
Merck
Pfizer
Sanofi
Alnylam Pharmaceuticals
Amarin Corporation
Amgen
Bristol-Myers Squibb
Catabasis Pharmaceuticals
Cerenis
Cipla
CJ HealthCare
CKD Bio
Daewoong Pharmaceutical
Daiichi Sankyo
Eli Lilly
Esperion Therapeutics
GlaxoSmithKline
JW Pharmaceuticals
Kadmon Pharmaceuticals
Lupin Pharmaceuticals
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Statins
Cholesterol absorption inhibitors
Dyslipidemia injectable
Segment by Application
Hospitals and Clinics
Medical Laboratories
Drug Stores
Others
Table of Contents
Executive Summary
1 Dyslipidemia Drugs Market Overview
- 1.1 Product Overview and Scope of Dyslipidemia Drugs
- 1.2 Dyslipidemia Drugs Segment by Type
- 1.2.1 Global Dyslipidemia Drugs Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Statins
- 1.2.3 Cholesterol absorption inhibitors
- 1.2.4 Dyslipidemia injectable
- 1.3 Dyslipidemia Drugs Segment by Application
- 1.3.1 Dyslipidemia Drugs Consumption Comparison by Application (2014-2025)
- 1.3.2 Hospitals and Clinics
- 1.3.3 Medical Laboratories
- 1.3.4 Drug Stores
- 1.3.5 Others
- 1.4 Global Dyslipidemia Drugs Market by Region
- 1.4.1 Global Dyslipidemia Drugs Market Size Region
- 1.4.2 North America Status and Prospect (2014-2025)
- 1.4.3 Europe Status and Prospect (2014-2025)
- 1.4.4 China Status and Prospect (2014-2025)
- 1.4.5 Japan Status and Prospect (2014-2025)
- 1.5 Global Dyslipidemia Drugs Market Size
- 1.5.1 Global Dyslipidemia Drugs Revenue (2014-2025)
- 1.5.2 Global Dyslipidemia Drugs Production (2014-2025)
2 Global Dyslipidemia Drugs Market Competition by Manufacturers
- 2.1 Global Dyslipidemia Drugs Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Dyslipidemia Drugs Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Dyslipidemia Drugs Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Dyslipidemia Drugs Production Sites, Area Served, Product Types
- 2.5 Dyslipidemia Drugs Market Competitive Situation and Trends
- 2.5.1 Dyslipidemia Drugs Market Concentration Rate
- 2.5.2 Dyslipidemia Drugs Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Dyslipidemia Drugs Production Market Share by Regions
- 3.1 Global Dyslipidemia Drugs Production Market Share by Regions
- 3.2 Global Dyslipidemia Drugs Revenue Market Share by Regions (2014-2019)
- 3.3 Global Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Dyslipidemia Drugs Production
- 3.4.1 North America Dyslipidemia Drugs Production Growth Rate (2014-2019)
- 3.4.2 North America Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Dyslipidemia Drugs Production
- 3.5.1 Europe Dyslipidemia Drugs Production Growth Rate (2014-2019)
- 3.5.2 Europe Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Dyslipidemia Drugs Production (2014-2019)
- 3.6.1 China Dyslipidemia Drugs Production Growth Rate (2014-2019)
- 3.6.2 China Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Dyslipidemia Drugs Production (2014-2019)
- 3.7.1 Japan Dyslipidemia Drugs Production Growth Rate (2014-2019)
- 3.7.2 Japan Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Dyslipidemia Drugs Consumption by Regions
- 4.1 Global Dyslipidemia Drugs Consumption by Regions
- 4.2 North America Dyslipidemia Drugs Consumption (2014-2019)
- 4.3 Europe Dyslipidemia Drugs Consumption (2014-2019)
- 4.4 China Dyslipidemia Drugs Consumption (2014-2019)
- 4.5 Japan Dyslipidemia Drugs Consumption (2014-2019)
5 Global Dyslipidemia Drugs Production, Revenue, Price Trend by Type
- 5.1 Global Dyslipidemia Drugs Production Market Share by Type (2014-2019)
- 5.2 Global Dyslipidemia Drugs Revenue Market Share by Type (2014-2019)
- 5.3 Global Dyslipidemia Drugs Price by Type (2014-2019)
- 5.4 Global Dyslipidemia Drugs Production Growth by Type (2014-2019)
6 Global Dyslipidemia Drugs Market Analysis by Applications
- 6.1 Global Dyslipidemia Drugs Consumption Market Share by Application (2014-2019)
- 6.2 Global Dyslipidemia Drugs Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Dyslipidemia Drugs Business
- 7.1 AstraZeneca
- 7.1.1 AstraZeneca Dyslipidemia Drugs Production Sites and Area Served
- 7.1.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.1.3 AstraZeneca Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Merck
- 7.2.1 Merck Dyslipidemia Drugs Production Sites and Area Served
- 7.2.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.2.3 Merck Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Pfizer
- 7.3.1 Pfizer Dyslipidemia Drugs Production Sites and Area Served
- 7.3.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.3.3 Pfizer Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Sanofi
- 7.4.1 Sanofi Dyslipidemia Drugs Production Sites and Area Served
- 7.4.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.4.3 Sanofi Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 Alnylam Pharmaceuticals
- 7.5.1 Alnylam Pharmaceuticals Dyslipidemia Drugs Production Sites and Area Served
- 7.5.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.5.3 Alnylam Pharmaceuticals Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 Amarin Corporation
- 7.6.1 Amarin Corporation Dyslipidemia Drugs Production Sites and Area Served
- 7.6.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.6.3 Amarin Corporation Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
- 7.7 Amgen
- 7.7.1 Amgen Dyslipidemia Drugs Production Sites and Area Served
- 7.7.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.7.3 Amgen Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.7.4 Main Business and Markets Served
- 7.8 Bristol-Myers Squibb
- 7.8.1 Bristol-Myers Squibb Dyslipidemia Drugs Production Sites and Area Served
- 7.8.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.8.3 Bristol-Myers Squibb Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.8.4 Main Business and Markets Served
- 7.9 Catabasis Pharmaceuticals
- 7.9.1 Catabasis Pharmaceuticals Dyslipidemia Drugs Production Sites and Area Served
- 7.9.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.9.3 Catabasis Pharmaceuticals Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.9.4 Main Business and Markets Served
- 7.10 Cerenis
- 7.10.1 Cerenis Dyslipidemia Drugs Production Sites and Area Served
- 7.10.2 Dyslipidemia Drugs Product Introduction, Application and Specification
- 7.10.3 Cerenis Dyslipidemia Drugs Production, Revenue, Price and Gross Margin (2014-2019)
- 7.10.4 Main Business and Markets Served
- 7.11 Cipla
- 7.12 CJ HealthCare
- 7.13 CKD Bio
- 7.14 Daewoong Pharmaceutical
- 7.15 Daiichi Sankyo
- 7.16 Eli Lilly
- 7.17 Esperion Therapeutics
- 7.18 GlaxoSmithKline
- 7.19 JW Pharmaceuticals
- 7.20 Kadmon Pharmaceuticals
- 7.21 Lupin Pharmaceuticals
8 Dyslipidemia Drugs Manufacturing Cost Analysis
- 8.1 Dyslipidemia Drugs Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Dyslipidemia Drugs
- 8.4 Dyslipidemia Drugs Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Dyslipidemia Drugs Distributors List
- 9.3 Dyslipidemia Drugs Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Dyslipidemia Drugs Market Forecast
- 11.1 Global Dyslipidemia Drugs Production, Revenue Forecast
- 11.1.1 Global Dyslipidemia Drugs Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Dyslipidemia Drugs Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Dyslipidemia Drugs Price and Trend Forecast (2019-2025)
- 11.2 Global Dyslipidemia Drugs Production Forecast by Regions (2019-2025)
- 11.2.1 North America Dyslipidemia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Dyslipidemia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.3 China Dyslipidemia Drugs Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Dyslipidemia Drugs Production, Revenue Forecast (2019-2025)
- 11.3 Global Dyslipidemia Drugs Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Dyslipidemia Drugs Consumption Forecast (2019-2025)
- 11.3.2 Europe Dyslipidemia Drugs Consumption Forecast (2019-2025)
- 11.3.3 China Dyslipidemia Drugs Consumption Forecast (2019-2025)
- 11.3.4 Japan Dyslipidemia Drugs Consumption Forecast (2019-2025)
- 11.4 Global Dyslipidemia Drugs Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Dyslipidemia Drugs Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Dyslipidemia Drugs. Industry analysis & Market Report on Dyslipidemia Drugs is a syndicated market report, published as Global Dyslipidemia Drugs Market Research Report 2019. It is complete Research Study and Industry Analysis of Dyslipidemia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
